|
1
|
Ribatti D, Nico B, Crivellato E, Roccaro
AM and Vacca A: The history of the angiogenic switch concept.
Leukemia. 21:44–52. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun Y: The role of Chinese medicine in
clinical oncology. Chin J Integr Med. 20:3–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu YJ, Shen XL, Lu HL, Zhang YH, Huang XA,
Fu LC and Fong WF: Tenacigenin B derivatives reverse
P-glycoprotein-mediated multidrug resistance in HepG2/Dox cells. J
Nat Prod. 71:1049–1051. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li MQ, Shen JH, Xu B, et al: The mechanism
of laboratory research for xiaoaiping treating SGC-7901 gastric
carcinoma cellular strains. J Interventional Radiology. 10:228–231.
2001.(In Chinese).
|
|
5
|
Liang XH, Gao GH, Zhou XL, et al: The
anti-angiogenic effect of Xiaoaiping injection on Lewis lung
carcinoma in C57 mice. Chin Clin Oncol. 15:689–692. 2010.(In
Chinese).
|
|
6
|
Li D, Ou YJ, Li CP, et al: Marsdensia
tenacissima induces apoptosis of human U937, HL60 leukemic
cells. Chin J Biochem Pharm. 29:33–37. 2008.(In Chinese).
|
|
7
|
Chen B, Li CP, Chen JH, et al: Effect of
extract from Marsdenia tenacissima on Jurkat, Raji and
RPMI8226 cells in vitro. Chin J of Biochem Pharmc. 30:174–177.
2009.(In Chinese).
|
|
8
|
Fang YQ and Sun XM: Review on Marsdenia
tenacissima's chemical components and their antitumor
mechanism. Chin J of Biochem Pharmac. 32:165–167. 2011.(In
Chinese).
|
|
9
|
Editorial Committee of the pharmacopoeia
of People's Republic of China: The pharmacopoeia of People's
Republic of China, Part 1. Chemical Industry Press; Beijing, China:
pp. 442–443. 2005, (In Chinese).
|
|
10
|
Yao Q, Lu TL, Mao CQ, et al: Determination
of total saponins and tenac issoside-B in bark and kibe of
Marsdenia tenacissima. Anhui Med and Pharmac J. 14:36–38.
2010.(In Chinese).
|
|
11
|
Zhang M, Tang H, Guo Z, An H, Zhu X, Song
W, Guo J, Huang X, Chen T, Wang J and Cao X: Splenic stroma drives
mature dendritic cells to differentiate into regulatory dendritic
cells. Nat Immunol. 5:1124–1133. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Prabhakar BT, Khanum SA, Shashikanth S and
Salimath BP: Antiangiogenic effect of 2-benzoyl-phenoxy acetamide
in EAT cell is mediated by HIF-1alpha and down regulation of VEGF
of in-vivo. Invest New Drugs. 24:471–478. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Staton CA, Reed MW and Brown NJ: A
critical analysis of current in vitro and in vivo angiogenesis
assays. Int J Exp Pathol. 90:195–221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Folkman J: Proceeding: Tumor angiogenesis
factor. Cancer Res. 34:2109–2113. 1974.PubMed/NCBI
|
|
15
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jackson C: Matrix metalloproteinases and
angiogenesis. Curr Opin Nephrol Hypertens. 11:295–299. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang MS, Oh JS, Kang IC, Hong SJ and Choi
CH: Inhibitory effect of methyl gallate and gallic acid on oral
bacteria. J Microbiol. 46:744–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Talmadge JE, Singh RK, Fidler IJ and Raz
A: Murine models to evaluate novel and conventional therapeutic
strategies for cancer. Am J Pathol. 170:793–804. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Prabhakar BT, Khanum SA, Jayashree K,
Salimath BP and Shashikanth S: Anti-tumor and proapoptotic effect
of novel synthetic benzophenone analogues in Ehrlich ascites tumor
cells. Bioorg Med Chem. 14:435–446. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: Mechanisms of anti-tumor activity. Nat Rev Cancer.
8:579–591. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanada D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and
Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic
switch during carcinogenesis. Nat Cell Biol. 2:737–744. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: Trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Folkman J: Angiogenesis and apoptosis.
Semin Cancer Biol. 13:159–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Z, Lin H, Wang Y, Cao Z, Lin W and
Chen Q: Studies on the anti-angiogenic effect of Marsdenia
tenacissima extract in vitro and in vivo. Oncol Lett.
5:917–922. 2013.PubMed/NCBI
|
